bpc 157 pharmacokinetics half life study Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs Frontiers | Pharmacokinetics, distribution, metabolism,

The dorsal dural incisions were closed after careful exploration, followed by fixation and fusion of the L4-L5 levels

This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution

Shaheen NJ, Falk GW, Iyer PG, Gerson LB

TB-500 (Thymosin Beta-4 fragment): A synthetic heptapeptide (sequence Ac-Lys-Lys-Thr-Glu-Thr-Gln